



## NEWS RELEASE

### FOR IMMEDIATE RELEASE

**Contact:**

Sheryl Seapy, Pure Communications  
(949) 608-0841

### **XDx Approved as a Continuing Education Provider by the American Board for Transplant Certification**

*Certified Clinical Transplant Coordinators (CCTC), Certified Clinical Transplant Nurses (CCTN) and Certified Procurement Transplant Coordinators (CPTC) will receive Continuing Education Points for Transplant Certification (CEPTCs) for attending AlloMap<sup>®</sup> Workshops*

**BRISBANE, Calif., March 8, 2011** – XDx, Inc., a molecular diagnostics company focused on noninvasive gene expression tests to monitor immune-mediated conditions, today announced that the American Board for Transplant Certification (ABTC) has recognized XDx as an approved provider for continuing education. All workshops offered by XDx in 2011 will be approved for Continuing Education Points for Transplant Certification (CEPTCs). These workshops provide an opportunity for healthcare professionals to interact and enhance their understanding of the clinical utility of AlloMap<sup>®</sup>.

“We are pleased by ABTC’s decision, which will allow us to offer certified transplant nurses and transplant coordinators continuing education credit for their attendance at our workshops,” said Pierre Cassigneul, president and CEO of XDx. “Our clinical workshop curriculum helps healthcare professionals learn how AlloMap testing can enhance their patients’ post-heart transplant experience. To date, our workshops have been very well received and attended. The acceptance of credits for recertification by ABTC will further reward the participants for their educational effort.”

Following heart transplants, patients typically undergo multiple endomyocardial biopsies, an invasive method of monitoring for post-transplant rejection. AlloMap is a simple, non-invasive blood test that can help physicians evaluate whether a patient is at low risk for heart transplant rejection. There are about 2,100 heart transplants in the United States each year and approximately 20,000 living recipients of heart transplants.

For more information about the workshops, visit <http://allomap.com/resources-allomap-workshops-presentations.html>. To register for an AlloMap Clinical Workshop, please call (415) 287-2358 or email [clinicalforums@xdx.com](mailto:clinicalforums@xdx.com).

### **About AlloMap® Molecular Expression Technology**

AlloMap Molecular Expression Testing is a non-invasive gene expression test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with a standard clinical assessment. AlloMap testing measures the expression levels of 20 genes from a blood sample. The combined expression of these genes is represented as an AlloMap test score. AlloMap is performed in the XDx CLIA-certified laboratory and has been commercially available since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008.

### **About XDx**

XDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression-based tests for the monitoring of transplant rejection and autoimmune diseases. The company has developed AlloMap Molecular Expression Testing, an FDA-cleared test, which provides transplant physicians with a tool to aid in the determination of the probability of acute cellular rejection for post-cardiac transplant patient management. Some of the AlloMap technology developed and implemented by XDx in heart transplant patient management may be applicable to other conditions that involve transplant rejection and diseases that affect the immune system. XDx's non-invasive technology offers the potential to decrease healthcare costs and improve the quality of life for patients with a variety of life-threatening or life-altering immune-mediated diseases. For more information, please visit [www.xdx.com](http://www.xdx.com).

###